About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...

The Department of Health said the decision reflects its mandate to ensure that all citizens have access to safe, effective, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly ...

Around 1,000 doses of Gilead Sciences' HIV prevention drug, lenacapavir, were sent to Zambia and Eswatini under a U.S.

Discover how lenacapavir and bNAbs show high HIV-1 suppression, low resistance, and promising outcomes for future treatment ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...

The Department of Health’s National Essential Medicines List Committee (NEMLC) has approved the addition of the recently ...

Amid steep cuts to US foreign assistance, the Trump administration is touting a new plan to provide a powerful HIV-prevention ...

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...